Roche 454 Life Sciences and Roche Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
Published: May 09, 2012
454 Life Sciences, a Roche Company, and SoftGenetics announced today that the two firms have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe® software.
NextGENe® software is a free standing biologist-friendly software multi-package that is fully compatibility with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling and more. The software package provides additional options for users of 454 Sequencing Systems, in addition to the extensive GS Data Analysis Software suite provided with the platforms.
"This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace," states SoftGenetics co-founder John Fosnacht. "SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only delivers the required quality and sensitivity, but also the efficiency needed in today's scientific and economic environments."
SoftGenetics offers 30-day trials and no cost web-based training on its genetic analysis software packages. Interested parties may request the software on the company website at http://www.softgenetics.com or via email at firstname.lastname@example.org.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in
Chugai Pharmaceutical, Japan. For more information: http://www.roche.com
SoftGenetics, LLC specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy to use Windows® user interface.
For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, and 454 SEQUENCING, and are trademarks of Roche.
The name "SoftGenetics," the SoftGenetics logo, NextGENe, and the NextGENe Condensation Tool are trademarks or registered trademarks of SoftGenetics, LLC.
All other product names and trademarks are the property of their respective owners.
For further information please contact:
Dr. Burkhard Ziebolz
454 Life Sciences Corporation, a Roche Company
SOURCE Roche Diagnostics GmbH